Allergan strengthens women’s health focus with $26m buy

Allergan has boosted its focus on women’s health with the acquisition of Repros Therapeutics, a development stage biopharmaceutical company.

Repros develops new drugs to treat hormonal and reproductive system disorders.

Announced yesterday, December 12, the deal will see Allergan purchase the company for $0.67 a share, so with 39.56 million shares, this amounts to approximately $26 million.

The acquisition falls into women’s health, which is one of Allergan’s six focuses. The other five therapeutic categories are central nervous system, eye care, dermatology, gastroenterology, and urology.

Back in July, Repros revealed that its oral delivery mechanism for Proellex (telapristone acetate) had hit a roadblock, which is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis.

Proellex was put on partial clinical hold by the Food and Drug Administration, which indicated that Repros will have to compile a large pre-approval safety database to support future development.

The chemical acts a selective blocker of the progesterone receptor.

The National Uterine Fibroids Foundation estimates that 80% of all women in the US have uterine fibroids, and one in four of these women have symptoms severe enough to require treatment.

Pending approvals, Repros expects the transaction to close during the first quarter of 2018.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories like this sent straight to your inbox.